IPCA posts 42% rise in net to Rs 35 cr
CORPORATE SCORECARD
| Total Income (net of excise & sales tax) has increased by 11 per cent from Rs 222 crore for the quarter ended June 30, 2006 to Rs 247.2 crore for the quarter ended June 30, 2007. |
| Recently Ipca received the US Food and Drug Administration (FDA) approval for hydroxychloroquine sulfate tablets, with annual sales of $50 million in the US and roped in Ranbaxy Pharmaceuticals as its partner to commercialise this product in the US market. |
| Three products of Ipca are marketed in the US by Ranbaxy, the other two are Furosemide and Atenolol tablets. |
| Ipca is one of the largest producers of the active pharmaceutical ingredient hydroxychloroquine sulfate in the world and has registrations in various countries. |
| Ipca's share prices closed on the Bombay Stock Exchange (BSE) today at Rs 715, an increase of 1.21 per cent, from the previous day close of Rs706.45. |